HC Wainwright Raises GeoVax Labs (NASDAQ:GOVX) Price Target to $120.00

GeoVax Labs (NASDAQ:GOVX) had its target price increased by equities research analysts at HC Wainwright from $8.00 to $120.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock.

GeoVax Labs Trading Up 71.2 %

NASDAQ GOVX opened at $1.90 on Tuesday. The stock has a 50-day simple moving average of $1.62 and a two-hundred day simple moving average of $2.87. GeoVax Labs has a fifty-two week low of $1.09 and a fifty-two week high of $10.24.

GeoVax Labs (NASDAQ:GOVX) last announced its quarterly earnings results on Tuesday, May 14th. The company reported ($2.47) earnings per share for the quarter.

Institutional Trading of GeoVax Labs

A hedge fund recently bought a new stake in GeoVax Labs stock. Armistice Capital LLC acquired a new position in GeoVax Labs, Inc. (NASDAQ:GOVX) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,626,516 shares of the company’s stock, valued at approximately $587,000. Armistice Capital LLC owned 91.38% of GeoVax Labs as of its most recent filing with the Securities & Exchange Commission. 6.09% of the stock is owned by institutional investors and hedge funds.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.